“Eculizumab First” in the Management of Posttransplant Thrombotic Microangiopathy

“Eculizumab First” in the Management of Posttransplant Thrombotic Microangiopathy

Introduction: Posttransplant thrombotic microangiopathy (PT-TMA) is an uncommon event that characterizes approximately 3% to 14% of kidney transplants (KTs), and that is associated with a higher risk of delayed graft function and graft loss. PT-TMA occurs more frequently within the first 3 months af...

Full description

Saved in:
Bibliographic Details
Main Authors: Federica Maritati, Valeria Corradetti, Claudia Bini, Michele Provenzano, Vania Cuna, Marco Busutti, Francesco Tondolo, Fulvia Zappulo, Gisella Vischini, Francesca Iacovella, Chiara Abenavoli, Greta Borelli, Marcello Demetri, Benedetta Fabbrizio, Giorgia Radi, Matteo Ravaioli, Caterina Mele, Gaetano La Manna, Giorgia Comai
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Kidney International Reports
Subjects:
thrombotic microangiopathy
atypical hemolytic uremic syndrome
kidney transplant
eculizumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924000147
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items